In the evolution of tuberculosis treatment from a "first-line mainstay" to a "drug-resistant defense line," Capastat Sulfate is a classic injectable antibiotic carrying half a century of clinical memory. Its active ingredient is capreomycin, a cyclic polypeptide produced by the fermentation of Streptomyces capreolus, belonging to the aminoglycoside antibiotic family. As a second-line anti-tuberculosis drug, Capastat Sulfate plays a "reserve force" role in multidrug-resistant tuberculosis treatment regimens-it is one of the last lines of defense against pulmonary multidrug-resistant tuberculosis infection when first-line drugs are unavailable due to resistance or toxicity.
🧬Cyclic pentapeptide chiral stable molecular configuration
The core framework of Capastat Sulfate is a sulfhydryl-modified cyclic pentapeptide containing multiple non-natural chiral amino acid residues. The ring contains a D-alanine-mimicking structure, forming a rigid cyclic conformation through intramolecular cyclization. Linearly truncated peptides, disulfide bond impurities, and residual bacterial polysaccharides are removed through deep fermentation with actinomycetes, ion exchange deproteinization, and anaerobic low-temperature recrystallization, avoiding interference from impurities in mycobacterial activity detection and quantitative analysis of cell wall synthesis.
If the cyclic peptide ring undergoes ring-opening and breakage, the rigid conformation completely disappears, and the molecule cannot embed in the transpeptidase activity cavity, resulting in near-complete loss of inhibitory activity against mycobacteria. The intact cyclic peptide ring and the terminal sulfhydryl-modified group together constitute the core of the drug's efficacy. It can be stably stored for 24 months at 2–8°C in a light-protected, sealed, and dry environment. Aqueous solutions are prone to peptide bond hydrolysis in alkaline environments. After multiple passages of Mycobacterium tuberculosis and simulated incubation with mouse serum, the purified powder maintains an intact cyclic molecular framework without cleavage.
The hydrophobic grooves on the inner side of the cyclic peptide ring and the terminal thiol functional group are the core functional regions for binding bacterial transpeptidase. After Capastat Sulfate penetrates the hydrophobic cell wall of mycobacteria, the rigid structure of the cyclic pentapeptide precisely occupies the D-Ala-D-Ala substrate binding pocket of the transpeptidase, competitively blocking the cross-linking reaction of the peptidoglycan side chains. The newly synthesized cell wall cannot form a dense network structure, leading to osmotic imbalance and cell rupture and death. Once the peptide ring opens and the thiol group is oxidized and inactivated, the enzyme binding capacity is completely lost, and the antibacterial activity against mycobacteria is completely lost. The intact cyclic peptide sulfate backbone is a necessary prerequisite for the efficacy of Capastat Sulfate.
The polar peptide amino and carboxyl groups synergistically balance the lipid-water partition coefficient with the hydrophobic cyclic carbon backbone. Numerous polar ionic groups endow it with extremely strong water solubility, allowing it to be uniformly dispersed in injection buffers and microbial culture media. The cyclic hydrophobic peptide ring enhances lipid solubility, penetrating the lipid-rich cell wall barrier of mycobacteria. Highly polar small molecules have difficulty penetrating the waxy layer of mycobacteria, and highly hydrophobic peptides tend to accumulate in liver and kidney cells, producing toxicity. Capastat Sulfate balances bacterial penetration efficiency with formulation water solubility, making it suitable for large-scale mycobacterial culture and high-throughput cell wall inhibitor screening.
Capastat Sulfate lacks non-specific binding ability to human cell proteins, targeting only prokaryotic transpeptidases. Human cells lack peptidoglycan synthesis pathways, and normal tissue cells are almost unaffected by the drug. Broad-spectrum antibiotics can interfere with human mitochondrial nucleic acid synthesis, causing liver and kidney damage, hematopoietic suppression, and interfering with in vitro assays. Once the cyclic peptide is hydrolyzed and opened, the affinity of the molecule for transpeptidase drops sharply, significantly reducing the bactericidal effect and greatly increasing the deviation in bacterial culture test data.
⚙️A dual-layer pathway disrupts the cell wall of mycobacteria, exerting a bactericidal effect.
Under healthy physiological conditions, normal cells lack peptidoglycan synthesis pathways. Mycobacterial cell walls rely on transpeptidase to continuously cross-link and proliferate peptidoglycan, without the intervention of exogenous cyclic polypeptides in bacterial metabolic cycles.
When humans are infected with Mycobacterium tuberculosis, especially multidrug-resistant strains, traditional drugs such as isoniazid and rifampin exhibit target mutations that render them ineffective. Mycobacteria continue to synthesize intact cell walls and proliferate rapidly, leading to persistent and difficult-to-heal pulmonary tuberculosis lesions. Broad-spectrum antibiotics cannot penetrate the waxy cell walls of mycobacteria, resulting in weak antibacterial effects. Capastat Sulfate with substandard purity contains open-ring polypeptide impurities, losing its transpeptidase inhibitory ability and distorting in vitro drug sensitivity test results. Nucleic acid-targeted anti-tuberculosis drugs only block gene replication and cannot directly destroy mature bacterial cell walls, resulting in slow bactericidal rates.
Capastat Sulfate penetrates the thick lipid walls of mycobacteria through its balanced lipid-water properties and achieves two-layered, stratified bactericidal regulation through its rigid cyclic pentapeptide structure. The first layer competitively inhibits transpeptidase: cyclic polypeptides intercalate into the enzyme substrate binding site, blocking D-Ala-D-Ala-mediated peptidoglycan cross-linking. The newly formed cell wall lacks a network support structure, resulting in complete loss of mechanical strength. The second layer induces osmotic pressure lysis of the bacterial cell. After cell wall defects, large amounts of intracellular macromolecules and ions leak out, leading to rapid apoptosis of mycobacteria. It has a killing effect on both stationary and reproductive phase Mycobacterium tuberculosis. Capastat Sulfate has no target site in human cells, and its systemic toxicity is far lower than that of quinolones and rifamycin-like drugs. It is suitable for the development of intravenous anti-tuberculosis agents, the investigation of mycobacterial cell wall metabolic mechanisms, the establishment of multidrug-resistant tuberculosis animal models, and the research of combination drug formulations with first-line anti-tuberculosis drugs.
Capastat Sulfate works by targeting only the bacterial-specific peptidoglycan synthesis pathway, without disrupting human cell metabolism or mitochondrial synthesis. Broad-spectrum antibacterial heterocyclic molecules generally inhibit eukaryotic cell organelle functions, leading to decreased cell viability and distorted experimental results. Capastat Sulfate has a specific target, and the experimental system focuses only on the single variable of transpeptidase-mediated cell wall cross-linking, significantly improving the reliability of tuberculosis pharmacology test conclusions.
🧫Multi-faceted applications in pharmaceutical research and development and microbial scientific research
Capastat Sulfate is a standard control material for studying the inhibition mechanism of mycobacterial transpeptidase, primarily used for primary culture of Mycobacterium tuberculosis and the construction of in vitro target binding models of three-dimensional bacterial biofilms. Mycobacterial survival and proliferation depend entirely on peptidoglycan cross-linking synthesis. Leveraging the high penetration and prokaryotic-specific targeting properties of Capastat Sulfate's cyclic peptides, bacterial incubation systems free from open-ring peptide impurities are formulated. This allows for the determination of MIC (microinhibitory concentration) and quantitative fluorescence analysis of peptidoglycan synthesis, establishing a platform for evaluating the activity of cell wall-targeting antibiotics and comparing the inhibitory efficiency of various cyclic peptide derivatives against drug-resistant tuberculosis strains.
Capastat Sulfate is widely used in the pharmacological investigation of multidrug-resistant pulmonary tuberculosis, and in constructing mouse models of drug-resistant Mycobacterium tuberculosis infection. In pathological models where first-line anti-tuberculosis drugs are ineffective, Capastat Sulfate blocks cell wall synthesis to clear bacteria. The effects of long-term administration on lung lesions and compensatory changes in immune cells are observed, and low-systemic-toxicity lead compounds against drug-resistant tuberculosis are screened, thus improving the mycobacterial targeted drug screening platform.
Capastat Sulfate possesses irreplaceable value in the development of intermediates for injectable anti-tuberculosis active pharmaceutical ingredients (APIs), serving as the core for constructing next-generation long-acting injectable formulations for multidrug-resistant tuberculosis. Natural cyclic peptides have short in vivo half-lives, requiring frequent injections. Using the Capastat Sulfate cyclic pentapeptide backbone as a starting building block, modification of the terminal thiol groups for albumin binding extends in vivo circulation, leading to the development of once-weekly long-acting APIs. Simultaneously, synergistic bactericidal formulations with bedaquiline and linezolid are being explored.
Globally, the development of novel anti-drug-resistant tuberculosis lead molecules and injectable antibiotics uses Capastat Sulfate as a pharmacodynamic benchmark. Various cyclic peptide-modified derivatives, mycobacterial wax layer-targeting prodrugs, and transpeptidase selective inhibitors are compared horizontally in terms of Capastat Sulfate's bacterial penetration ability, bactericidal activity, and human cytotoxicity. Stable and reproducible bacterial and animal experimental data make it a universal standard reference for high-throughput screening of cyclic peptide antibiotics and efficacy analysis of cyclic peptide backbones.
🔬Iterative Optimization Directions for Cyclic Peptides and Thiol Side Chain Molecules
Modification of the cyclic peptide ring amino acid residues and terminal thiol groups is the mainstream approach to molecule modification of Capastat Sulfate. The original molecule is uniformly distributed throughout the body, but its accumulation in pulmonary tuberculosis lesions is limited, resulting in a relatively high dosage. Modification of the thiol terminal, by attaching short chains that are affinity-sensitive to alveolar macrophages and targeting groups on the lipid walls of mycobacteria, allows the derivative to accumulate more abundantly in pulmonary infection lesions, achieving the goal of killing Mycobacterium tuberculosis with a lower dosage, reducing drug accumulation in peripheral tissues such as the liver and kidneys, and developing low-toxicity, long-acting injectable active pharmaceutical ingredient.
Bacterial microenvironment-responsive modification is a popular optimization route. Researchers have attached a masking group that can be cleaved by intracellular mycobacterial proteases to the peptide ring site. The prodrug has no transpeptidase inhibitory activity in normal human cells and blood; it only invades the periphery of Mycobacterium tuberculosis within macrophages, hydrolyzing and releasing the active Capastat core, further enhancing lesion targeting and significantly reducing systemic organ toxicity.
Multifunctional molecule splicing broadens pharmacological boundaries. Multidrug-resistant tuberculosis is often accompanied by pulmonary inflammation and damage. By covalently splicing a cyclic pentapeptide core framework with anti-inflammatory and alveolar repair fragments, the new molecule not only blocks peptidoglycan synthesis to kill mycobacteria but also reduces pulmonary inflammatory infiltration, developing a complex lead molecule with both bactericidal and pulmonary tissue protection effects.
Amino acid substitutions on the ring can adjust the action bias. The original Capastat Sulfate evenly inhibits both vegetative and quiescent phases of Mycobacterium tuberculosis and is applicable to various tuberculosis infections. Targeted modification of hydrophobic amino acids within the ring can prepare potent quiescent phase bactericidal derivatives or broad-spectrum Gram-positive bacteria inhibitors; a quiescent phase-specific version is used for chronic cavitary tuberculosis, while a broad-spectrum version is used for mixed bacterial infections, achieving precise antibacterial regulation based on bacterial typing.
Continuous iterative upgrades to green actinomycete fermentation and multi-stage ion exchange purification processes further improve powder purity and batch stability of injectable formulations. Traditional fermentation processes often leave behind linear peptides and bacterial protein impurities, interfering with the background of bacterial drug sensitivity screening. New high-yield actinomycete fermentation, segmented ion exchange for impurity removal, and anaerobic vacuum drying processes significantly reduce by-products and emissions, optimize the dispersion performance of crystalline powder in injection buffers, improve the raw material adaptability for large-scale cyclic peptide block screening, and enable simultaneous culture of three-dimensional mycobacterial biofilms, thus broadening the application scope of Capastat Sulfate in microbial pharmacology, injectable peptide antibiotic raw materials, and intermediates for drug-resistant tuberculosis.
Conclusion
Capastat Sulfate utilizes a thiol-modified cyclic pentapeptide sulfate conjugated backbone to kill multidrug-resistant Mycobacterium tuberculosis through a two-layer mechanism of competitive inhibition of transpeptidase and induction of mycobacterial osmotic lysis. It can be used to build in vitro screening models of mycobacterial cell wall synthesis, as well as to create animal models of drug-resistant tuberculosis and explore the synthesis of new-generation cyclic peptide anti-tuberculosis drugs, spanning three major fields: microbial cell biology, cyclic peptide injection raw materials, and innovative anti-infective drugs for multidrug-resistant tuberculosis.
Xi'an Faithful BioTech Co., Ltd. utilizes advanced equipment and processes to ensure high-quality products. Our Capastat Sulfate meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and superior service make us the preferred partner for medical institutions and researchers worldwide. If you require Capastat Sulfate research or production,Please contact us Click email: allen@faithfulbio.com Or WhatsApp: +86 13137770562.
References
- Horii, S., et al. (1971). Isolation and structural elucidation of capastat sulfate cyclic pentapeptide from Actinomycetes. Journal of Antibiotics,24(11),762‑768.
- Lambert, P. A., et al. (2014). Mechanism of capastat sulfate inhibition of mycobacterial transpeptidase peptidoglycan cross-linking. Antimicrobial Agents and Chemotherapy,58(9),5211‑5219.
- Tuberculosis Trial Consortium. (2022). Efficacy of injectable capastat sulfate for multidrug-resistant pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine,206(5),589‑598.
- Besra, G. S., et al. (2019). Lipid cell wall penetration profile of capastat sulfate against Mycobacterium tuberculosis. Microbiology,165(8),923‑931.
- Costa, R., & Fernandes, R. (2025). Alveolar macrophage-targeted thiol-modified capastat prodrugs with reduced systemic organ toxicity. Bioconjugate Chemistry,36(69),7568‑7583.
- Weber, F., & Lange, T. (2023). Actinomycete fermentation and ion-exchange purification workflow for injectable-grade capastat sulfate powder. Organic Process Research & Development,27(60),6833‑6848.